Clar, K.L.; Weber, L.M.; Schmied, B.J.; Heitmann, J.S.; Marconato, M.; Tandler, C.; Schneider, P.; Salih, H.R.
Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course. Cancers 2021, 13, 6122.
https://doi.org/10.3390/cancers13236122
AMA Style
Clar KL, Weber LM, Schmied BJ, Heitmann JS, Marconato M, Tandler C, Schneider P, Salih HR.
Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course. Cancers. 2021; 13(23):6122.
https://doi.org/10.3390/cancers13236122
Chicago/Turabian Style
Clar, Kim L., Lisa M. Weber, Bastian J. Schmied, Jonas S. Heitmann, Maddalena Marconato, Claudia Tandler, Pascal Schneider, and Helmut R. Salih.
2021. "Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course" Cancers 13, no. 23: 6122.
https://doi.org/10.3390/cancers13236122
APA Style
Clar, K. L., Weber, L. M., Schmied, B. J., Heitmann, J. S., Marconato, M., Tandler, C., Schneider, P., & Salih, H. R.
(2021). Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course. Cancers, 13(23), 6122.
https://doi.org/10.3390/cancers13236122